Evidence map›Paper›PMID 39272982›Full record

ArticleCells2024

The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer.

Kana Shibata, Nobutaka Koibuchi, Fumihiro Sanada, Naruto Katsuragi, Yuko Kanemoto, Yasuo Tsunetoshi, Shoji Ikebe, Koichi Yamamoto, Ryuichi Morishita, Kenzo Shimazu and 1 more

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kana ShibataDepartment of Advanced Molecular Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Nobutaka KoibuchiDepartment of Advanced Molecular Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Fumihiro SanadaDepartment of Clinical Gene Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.ORCID 0000-0002-3728-5607
Naruto KatsuragiDepartment of Advanced Molecular Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Yuko KanemotoDepartment of Breast and Endocrine Surgery, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Yasuo TsunetoshiDepartment of Geriatric and General Medicine, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Shoji IkebeGraduate School of Dentistry (Oral and Maxillofacial Surgery), Osaka Dental University, Hirakata 573-1121, Japan.
Koichi YamamotoDepartment of Geriatric and General Medicine, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Ryuichi MorishitaDepartment of Clinical Gene Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Kenzo ShimazuDepartment of Breast and Endocrine Surgery, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
Yoshiaki TaniyamaDepartment of Advanced Molecular Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.ORCID 0000-0002-6057-7982

Funding

Grants in Aid for Scientific Research 24K11740START Project of the Ministry of Education, Culture, Sports, Science and Technology MEXT, funding number 12103677
6 · The paper itself

Abstract

backgroundPeriostin (POSTN) is a type of matrix protein that functions by binding to other matrix proteins, cell surface receptors, or other molecules, such as cytokines and proteases. POSTN has four major splicing variants (PN1-4), which are primarily expressed in fibroblasts and cancer. We have reported that we should inhibit pathological POSTN (PN1-3), but not physiological POSTN (PN4). In particular, pathological POSTN with exon 17 is present in both stroma and cancer, but it is unclear whether the stroma or cancer pathological POSTN should be suppressed. METHODS AND

resultsWe transplanted 4T1 cells (breast cancer) secreting POSTN with exon 17 into 17KO mice lacking POSTN exon 17 to suppress stromal POSTN with exon 17. The results show that 17KO mice had smaller primary tumors and fewer metastases. Furthermore, to suppress cancer POSTN with exon 17, 4T1 cells transfected with POSTN exon 17 skipping oligo or control oligo were transplanted from the tail vein into the lungs. The results show that POSTN exon 17 skipping oligo significantly suppressed lung metastasis.

conclusionsThese findings suggest that it is important to suppress POSTN exon 17 in both stroma and cancer. Antibody targeting POSTN exon 17 may be a therapeutic candidate for breast cancer.

Indexed as

Cell Adhesion MoleculesExonsStromal CellsAlternative SplicingAnimalsBreast NeoplasmsCell Line, TumorFemaleHumansLung NeoplasmsMiceMice, Inbred BALB CMice, KnockoutPeriostinCell Adhesion MoleculesPeriostinPOSTN protein, humanPostn protein, mousebreast cancercancer-associated fibroblasts (CAFs)periostinstromatumor-associated macrophages (TAMs)tumor microenvironment (TME)

Identifiers

PMID39272982
PMCPMC11394140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.